Original StudyPrognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non–Small-Cell Lung Cancer After Curative Resection
Introduction
Stage IIIA-N2 non–small-cell lung cancer (NSCLC) is a potentially operable, locally advanced disease. Because pathologically confirmed N2 (pN2) disease is classified according to the presence of mediastinal nodal metastasis regardless of its extent, it includes a broad spectrum of presentations, from occult disease to multiple mediastinal nodal metastases. As a consequence, stage IIIA-N2 NSCLC has been linked to a variable prognosis in previous studies, with 5-year survival rates ranging from 6% to 35%.1, 2
Although cisplatin-based adjuvant chemotherapy has led to significant improvements in survival in patients with resected NSCLC, particularly stage II and IIIA disease,3, 4, 5 the optimal management of stage IIIA-pN2 disease remains largely unknown, mainly as a result of the prognostic heterogeneity of this patient subgroup. With the hypothesis that the extent of pN2 metastasis may have prognostic relevance in patients with curatively resected stage IIIA-N2 NSCLC, several subclassifications of patients with pN2 disease have been proposed to improve staging—for example, based on skip pN2 metastasis6, 7 or pN2 nodal station numbers.8, 9, 10, 11, 12 Although the prognostic implication of the number of metastatic lymph nodes in resected NSCLC has been explored in previous studies, its relevance in pathologic stage IIIA-N2 disease has not been clearly demonstrated.13, 14, 15 To investigate this, we retrospectively assessed whether the risk of disease relapse and survival after complete surgical resection could be stratified according to the number of metastatic pN2 lymph nodes in patients with IIIA-N2 NSCLC.
Section snippets
Patients
Between January 1997 and December 2004, 250 patients with pathologically confirmed stage IIIA-N2 NSCLC were selected for inclusion from a prospectively collected patient database of the Asan Medical Center, Seoul, Korea. According to the preoperative staging assessment, all patients were determined to have curatively resectable disease by the attending surgeons. Of these, 44 patients were excluded as a result of preoperative induction chemotherapy (n = 28), incomplete resection (n = 11), and
Patient Characteristics
The patients' baseline characteristics are summarized in Table 1. The median age was 59 years, and 145 patients (71%) were male. Significant weight loss was reported in 34 patients (17%) at the time of diagnosis. In 73 patients (35%), PET scan was performed for initial clinical staging. N2 nodal metastasis was predicted in 68 patients (33%) at the preoperative staging assessment, and pneumonectomy was performed in 43 patients (21%). According to the number of pN2 metastases, 83 patients (40%)
Discussion
The prognosis of patients with resected stage IIIA-N2 NSCLC is heterogeneous, and better prognostic prediction is required for tailored therapy in this group of patients. However, many researchers have indicated that in patients with NSCLC, the current tumor, node, metastasis staging classification system does not accurately reflect the extent of mediastinal nodal metastasis that may be closely associated with survival outcomes. To circumvent this problem, a variety of pN2 subclassifications
Conclusion
The number of metastatic pN2 lymph nodes is an independent predictor of DFS and OS in patients with stage IIIA-N2 NSCLC after curative surgery. This may have an application in clinical practice and trials, where risk stratification is important. Further studies to validate this pN2 subclassification in other populations are warranted.
Disclosure
The authors have stated that they have no conflicts of interest.
References (22)
- et al.
Clinical prognostic factors in surgically treated stage IIIA–N2 non–small cell lung cancer: analysis of the literature
Lung Cancer
(1998) - et al.
The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of Malignant Tumours
J Thorac Oncol
(2007) - et al.
Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non–small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial
Lancet Oncol
(2006) - et al.
Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis
Ann Thorac Surg
(2005) - et al.
Skip mediastinal nodal metastases in the IIIa/N2 non–small cell lung cancer
J Thorac Oncol
(2007) - et al.
Survival and prognostic factors in resected N2 non–small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group
Ann Thorac Surg
(1997) - et al.
Prolonged survival in patients with resected non–small cell lung cancer and single-level N2 disease
J Thorac Cardiovasc Surg
(2004) - et al.
Completely resected stage IIIA non–small cell lung cancer: the significance of primary tumor location and N2 station
J Thorac Cardiovasc Surg
(2001) - et al.
Which is the better prognostic factor for resected non–small cell lung cancer: the number of metastatic lymph nodes or the currently used nodal stage classification?
J Thorac Oncol
(2011) - et al.
Significance of the number of positive lymph nodes in resected non–small cell lung cancer
J Thorac Oncol
(2006)
Number of metastatic lymph nodes in resected non–small cell lung cancer predicts patient survival
Ann Thorac Surg
Cited by (0)
This study was presented in part as a poster at the 2010 ASCO Annual Meeting, June 4-9, 2010, Chicago, IL, USA.